These results provide important information demonstrating that modulation of visfatin may be an appropriate pharmacological target for control of mucus-hypersecretion in treatment of airway inflammatory diseases in patients with obesity. This evidence concerns the gene NAMPT and obesity due to melanocortin 4 receptor deficiency.